Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis: SELECT-GCA

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis: SELECT-GCA

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary) ; Corticosteroid; Prednisolone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT-GCA
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 29 Apr 2025 According to an AbbVie media release, based upon results from this trial the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).
  • 08 Apr 2025 According to an AbbVie media release, data from this trial was recently published in the New England Journal of Medicine
  • 08 Apr 2025 According to an AbbVie media release, supported from data of this trial the European Commission (EC) granted marketing authorization to RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top